LEXARIA BIOSCIENCE CORP (LEXX) Stock Price, Quote, News and Overview
NASDAQ:LEXX - Nasdaq - US52886N4060 - Common Stock - Currency: USD
LEXX Quote, Performance and Key Statistics
1.45
+0.02 (+1.4%)
The current stock price of LEXX is 1.45 USD. In the past month the price decreased by -20.33%. In the past year, price decreased by -34.39%.
LEXX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About LEXX
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 5 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. The company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.
Company Info
LEXARIA BIOSCIENCE CORP
100 - 740 Mccurdy Road
Kelowna BRITISH COLUMBIA V1X 2P7 CA
CEO: Christopher Bunka
Employees: 5
Company Website: https://www.lexariabioscience.com/
Investor Relations: http://www.lexariaenergy.com/investors/
Phone: 12507656424
LEXARIA BIOSCIENCE CORP / LEXX FAQ
What is the stock price of LEXARIA BIOSCIENCE CORP today?
The current stock price of LEXX is 1.45 USD. The price increased by 1.4% in the last trading session.
What is the ticker symbol for LEXARIA BIOSCIENCE CORP stock?
The exchange symbol of LEXARIA BIOSCIENCE CORP is LEXX and it is listed on the Nasdaq exchange.
On which exchange is LEXX stock listed?
LEXX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEXARIA BIOSCIENCE CORP stock?
8 analysts have analysed LEXX and the average price target is 9.18 USD. This implies a price increase of 533.1% is expected in the next year compared to the current price of 1.45. Check the LEXARIA BIOSCIENCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEXARIA BIOSCIENCE CORP worth?
LEXARIA BIOSCIENCE CORP (LEXX) has a market capitalization of 25.45M USD. This makes LEXX a Nano Cap stock.
How many employees does LEXARIA BIOSCIENCE CORP have?
LEXARIA BIOSCIENCE CORP (LEXX) currently has 5 employees.
What are the support and resistance levels for LEXARIA BIOSCIENCE CORP (LEXX) stock?
LEXARIA BIOSCIENCE CORP (LEXX) has a resistance level at 1.61. Check the full technical report for a detailed analysis of LEXX support and resistance levels.
Is LEXARIA BIOSCIENCE CORP (LEXX) expected to grow?
The Revenue of LEXARIA BIOSCIENCE CORP (LEXX) is expected to grow by 51.14% in the next year. Check the estimates tab for more information on the LEXX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LEXARIA BIOSCIENCE CORP (LEXX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LEXX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LEXX, evaluating the profitability, health, valuation and growth aspects
- LEXARIA BIOSCIENCE CORP (LEXX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEXARIA BIOSCIENCE CORP (LEXX) Sales and EPS estimates to see what analysts future expectations are.
- LEXARIA BIOSCIENCE CORP (LEXX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEXARIA BIOSCIENCE CORP (LEXX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEXARIA BIOSCIENCE CORP (LEXX) Stock Chart to make your own analysis
- LEXARIA BIOSCIENCE CORP (LEXX) Latest news and press-releases to stay up to date.
Does LEXARIA BIOSCIENCE CORP (LEXX) stock pay dividends?
LEXX does not pay a dividend.
When does LEXARIA BIOSCIENCE CORP (LEXX) report earnings?
LEXARIA BIOSCIENCE CORP (LEXX) will report earnings on 2025-04-07.
What is the Price/Earnings (PE) ratio of LEXARIA BIOSCIENCE CORP (LEXX)?
LEXARIA BIOSCIENCE CORP (LEXX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
What is the Short Interest ratio of LEXARIA BIOSCIENCE CORP (LEXX) stock?
The outstanding short interest for LEXARIA BIOSCIENCE CORP (LEXX) is 3.77% of its float. Check the ownership tab for more information on the LEXX short interest.
LEXX Technical Analysis
LEXX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LEXX. While LEXX has a great health rating, there are worries on its profitability.
LEXX Financial Highlights
Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 43.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.74% | ||
| ROE | -74.89% | ||
| Debt/Equity | 0 |
LEXX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LEXX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -21.96% and a revenue growth 51.14% for LEXX